Zobrazeno 1 - 10
of 17
pro vyhledávání: ''
Autor:
Michael N Dalili, José A López-López, Deborah M Caldwell, Kyla H Thomas, Mark Stevenson, David Phillippo, Edna Keeney, Nicky J Welton, Marcus R. Munafò
Publikováno v:
Keeney, E, Welton, N J, Stevenson, M, Dalili, M N, López-López, J A, Caldwell, D M, Phillippo, D M, Munafò, M R & Thomas, K H 2021, ' Cost-Effectiveness Analysis of Smoking Cessation Interventions in the United Kingdom Accounting for Major Neuropsychiatric Adverse Events ', Value in Health, vol. 24, no. 6, pp. 780-788 . https://doi.org/10.1016/j.jval.2020.12.012
Value in Health
Value in Health
OBJECTIVES: Smoking is a leading cause of death worldwide. Cessation aids include varenicline, bupropion, nicotine replacement therapy (NRT), and e-cigarettes at various doses (low, standard and high) and used alone or in combination with each other.
Autor:
Edith A. Perez, Hans-Peter Goertz, Joseph B. Babigumira, Louis P. Garrison, Solomon J. Lubinga, C. Tournier
Publikováno v:
Value in Health. 22:408-415
Objective The APHINITY trial assessed the effectiveness and the safety of adding pertuzumab to trastuzumab and chemotherapy (THP) compared to trastuzumab and chemotherapy (TH) in the adjuvant management of human epidermal growth factor 2-positive (HE
Publikováno v:
Value in Health. 20:705-709
Background Economic evaluations often measure an intervention effect with mean overall survival (OS). Emerging types of cancer treatments offer the possibility of being "cured" in that patients can become long-term survivors whose risk of death is th
Autor:
Joan G. Meeder, Matthijs Versteegh, Maureen P.M.H. Rutten-van Mölken, Rudolf A. de Boer, Gerard C.M. Linssen, Jolanda M.A. Koenders, Isaac Corro Ramos
Publikováno v:
Value in Health, 20(10), 1260-1269. ELSEVIER SCIENCE INC
Value in Health. Elsevier Ltd.
Value in Health. Elsevier Ltd.
Objectives: To describe the adaptation of a global health economic model to determine whether treatment with the angiotensin receptor neprilysin inhibitor LCZ696 is cost effective compared with the angiotensin-converting enzyme inhibitor enalapril in
Publikováno v:
Value in Health. 18(7)
Autor:
Jinhyun Kim, Younhee Kim
Publikováno v:
Value in Health. 12:S78-S81
Objectives: This study aims to conduct an economic evaluation of oral deferasirox (DSX) compared with infusional deferoxamine (DFO) in patients with transfusional iron overload. Methods: Depending on the methods for measuring time-cost and convenienc
Autor:
Winfried V. Kern, Meinolf Karthaus, Jeroen P. Jansen, Ansgar Resch, Markus Ruhnke, Oliver A. Cornely, Andrew J. Ullmann
Publikováno v:
Value in Health. 9:12-23
Objective To assess the costs and cost-effectiveness of voriconazole in comparison to conventional amphotericin B (CAB) for the treatment of invasive aspergillosis in Germany. Methods The cost-effectiveness of voriconazole in comparison to CAB was ev
Autor:
Nicholas, Wells, Jayasena, Hettiarachchi, Michael, Drummond, Mcom, DPhil, David, Carter, Tamiza, Parpia, Francis, Pang
Publikováno v:
Value in Health. 6:438-447
Objectives This article explores the application of cost-effectiveness analysis in a comparison of eletriptan and sumatriptan in the acute treatment of migraine. Methods The study employs data from a randomized, double-blind, placebo-controlled clini
Publikováno v:
Value in Health, 18(7), A580-A581. ELSEVIER SCIENCE INC
Objectives: During the years, acute bacterial skin and skin structure infections (ABSSSIs) have seen an increase in incidence in many parts of the western world. Additionally, the treatment of ABSSSIs, generally consisting of surgical debridement or
Autor:
Massimo Valentino, Sergio Iannazzo, Maria De Francesco, Akash Nayak, Claudio Ronco, Stijn Vandekerckhove, Giovanni Morana
Publikováno v:
Value in Health. 16(7)
Background: Contrast-induced acute kidney injury (CI-AKI) is defined as a deterioration in renal function after administration of radiologic iodinated contrast media (CM). Iodixanol, showed a lower CI-AKI incidence than low-osmolar contrast media (LO